Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT
PARTICIPATION IN RESEARCH TOPIC UNDER MAJOR NATIONAL SCIENCE AND TECHNOLOGY PROJECT AND APPROVAL OF BEIJING KEY LABORATORY FOR DIGITAL HEALTHCARE FOR COGNITIVE IMPAIRMENT

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purposes of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that Beijing Zhijingling Technology Co., Ltd. (北京智精靈科技有限公司) ("**Zhijingling Technology**"), a wholly-owned subsidiary of the Company, as a key partner, has participated in the Major National Science and Technology Project on the prevention and treatment of cancer, cardiovascular and cerebrovascular, respiratory and metabolic diseases, with research topic titled "Establishment and Scenario-based Application of Key Technologies for Digital Diagnosis and Treatment of Intracranial Atherosclerotic Stenosis-Related Cognitive Impairment Based on Deep Reasoning Large Models" (Project No.: 2025ZD0546200) (the "**Project**" or the "**Major National Science and Technology Project**"). The Project has recently been officially launched. Meanwhile, the joint application for the "Beijing Key Laboratory for Digital Healthcare for Cognitive Impairment" by Zhijingling Technology and Xuanwu Hospital, Capital Medical University ("**Xuanwu Hospital**") and other entities has also been officially approved and established recently.

The Company's undertaking of the Major National Science and Technology Project and its obtaining approval of the Beijing Key Laboratory demonstrate the Company's technological advancement in the field of digital diagnosis and treatment for cognitive impairment.

I. BACKGROUND AND PRINCIPAL CONTENT OF THE MAJOR NATIONAL SCIENCE AND TECHNOLOGY PROJECT

Intracranial Atherosclerotic Stenosis ("**ICAS**") has a high prevalence of up to 13% in the population aged over 35 in China. Irreversible brain tissue damage caused by ICAS leads to cognitive impairment primarily manifesting as memory decline, language disorders, and executive dysfunction. Although nearly half of patients with moderate to severe ICAS have cognitive impairment, there is currently a lack of effective early diagnosis and treatment methods.

The newly launched research topic under the Major National Science and Technology Project focuses on the diagnostic and therapeutic challenges of ICAS-related cognitive impairment, and conducts systematic research leveraging the advantages of multidisciplinary integration. The core directions include establishing an assessment technology system and a deep reasoning prediction large model for ICAS-related cognitive impairment, to provide diagnostic and therapeutic tools for early screening, risk prediction and prevention, and intervention of the disease, and to establish a full-scenario closed-loop management system for ICAS-related cognitive impairment.

The implementation of the Project aims to establish an internationally leading diagnosis and treatment technology system for ICAS-related cognitive impairment, develop a disease management model in line with China's national conditions, effectively prevent and delay the progression of the disease, and facilitate the implementation of the "Healthy China" strategy. Led by Xuanwu Hospital, the Project is jointly tackled by Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Psychology of Chinese Academy of Sciences, Jilin University, Beijing Normal University, Zhijingling Technology, and other entities. The research team is composed of top experts in neurology, cognitive neuroscience, psychology and artificial intelligence, and has maintained long-term cooperation with international leading research teams, with multiple important results published in top journals such as Science and Cell, providing a solid guarantee for the successful implementation of the Project.

II. STRATEGIC SIGNIFICANCE OF THE MAJOR NATIONAL SCIENCE AND TECHNOLOGY PROJECT AND TASKS UNDERTAKEN BY THE COMPANY

The major national science and technology projects are major scientific and technological initiatives designed to achieve national strategic objectives and make breakthroughs in core and key technologies. The Project is a major national science and technology project research topic in the field of digital diagnosis and treatment for neurocognitive disorders in China, indicating that such direction has been acknowledged as part of national strategic scientific research.

As a pioneer in the deep integration of brain science and artificial intelligence technology, and leveraging its technology and data accumulation in the digital diagnosis and treatment of neurological and psychiatric diseases, the Company will be responsible for the research and development of deep reasoning large model technology for ICAS-related cognitive impairment, and the construction of the digital diagnosis and treatment platform, etc. in the Project.

III. RESEARCH DIRECTIONS OF THE "BEIJING KEY LABORATORY FOR DIGITAL HEALTHCARE FOR COGNITIVE IMPAIRMENT"

The Beijing Key Laboratory for Digital Healthcare for Cognitive Impairment (the "**Laboratory**" or the "**Beijing Key Laboratory**") is jointly established through the deep integration of clinical medicine, basic research, technology development and hardware innovation, forming a synergistic model characterized by "clinical-driven, basic research support, software-hardware integration, and seamless translation". As the core technology lead, the Company is primarily responsible for the core algorithm research and development of the digital healthcare platform for cognitive impairment, productization, and user experience optimization.

The laboratory will leverage the resource advantages of various parties, including artificial intelligence, on which the Company focuses, to empower the core technology research and development, clinical translation and industry standard setting for the digital diagnosis and treatment of cognitive impairment, build a high-level platform for academic exchange and talent cultivation, and promote the deep integration of digital healthcare technology and clinical diagnosis and treatment, so as to provide sustained momentum for innovative development of the industry.

IV. SIGNIFICANCE TO THE COMPANY

1. Research Strength and Industry Recognition

Participation in this Major National Science and Technology Project and the joint approval of the Beijing Key Laboratory with Xuanwu Hospital represent a strong recognition of the Company's overall scientific research and technological capabilities by the national and Beijing municipal government. This will significantly enhance the Company's high-level research planning and major project management capabilities. Through collaborative research with top-tier teams such as Xuanwu Hospital, the Company's R&D team will further develop clinical insight and capabilities in addressing complex medical challenges. This deep integration model of "industries, universities, research institutes and medical practitioners" will continuously generate high-quality academic achievements, greatly enhancing the Company's academic reputation and authority in the field of "digital therapeutics".

2. Leapfrog Advancement of Core Technologies

Participation in the Project will directly drive breakthrough improvements in the Company's core technologies in the digital diagnosis and treatment of cognitive impairment. Through collaboration with leading clinical centers, the Company will gain access to high-quality and standardized clinical data and deeply integrate AI large model technologies, which will not only optimize the precision and personalization of existing cognitive assessment and intervention solutions, but more importantly, enable the establishment of a cross-modal correlation analysis and prediction model from "cerebrovascular lesions" to "cognitive function". This represents a critical step for the Company's technology from "functional-level training" toward "etiological diagnosis and comprehensive management", contributing to the construction of higher technological barriers.

3. Strengthening of Commercial Network and Market Expansion

This cooperation provides the Company with another strong "authoritative endorsement" and strengthens its network establishment and cooperation depth with top medical institutions. The Company has established a joint scientific research and commercial cooperation network with over 200 hospitals in the past. The cooperation under the Major National Science and Technology Project and the Beijing Key Laboratory represents an "enhancement" to the existing industry-academia model. The outcomes and endorsements from the national-level projects will serve as a more powerful credential for market access of the Company's products to hospitals, especially top-tier Grade A hospitals, which will help shorten the market introduction cycle and further expand penetration into major professional medical markets including neurology, geriatrics, and cardiovascular medicine. This will drive upgrades in the Company's commercial model and facilitate business scale expansion.

As the Project is still in the research stage and the Laboratory is still in the preparatory stage, shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, December 22, 2025

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive Director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive Directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive Directors.